Roche vs Veeva

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.

Omnicom Appoints Tom Schwenger CEO of Health Marketing

Omnicom (NYSE: OMC) has appointed Tom Schwenger as Chief Executive Officer of Omnicom Health's marketing business, effective immediately. Schwenger, who brings over 35 years of experience in pharma, biotech, and healthcare, will oversee the group's global marketing agencies. He succeeds Dana Maiman, who is leaving the company. Schwenger will work with Michael Larson, who remains Chairman of Omnicom Health and will also oversee the specialty health business. The appointment aims to drive accelerated growth, innovation, and AI adoption for clients amid rapid healthcare market evolution. Schwenger joins from Veeva Systems, where he served as President and Chief Customer Officer and tripled revenue. Previously, he spent nearly three decades at Accenture, leading its life sciences practice.

• Omnicom appointed Tom Schwenger as CEO of Omnicom Health's marketing business.
• Tom Schwenger previously served as President and Chief Customer Officer at Veeva Systems.
• Dana Maiman is leaving Omnicom Health after leading the unit.

Veeva Summit to Showcase Agentic AI and Data Innovations

Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB, and other biopharma companies will present new strategies for commercial and medical excellence at the Veeva Commercial Summit, Europe, scheduled for November 18-19, 2026, in Copenhagen. The summit will showcase how industry-specific AI enables sales, marketing, and medical teams to improve customer engagement, derive insights, and accelerate compliant content delivery. Key topics include agentic customer engagement, agentic CRM, agentic MLR for content approvals, and building a data foundation for AI with HCP access data and trusted data platforms. The event will feature over 100 sessions and 1,200+ industry experts, highlighting innovations with Veeva's Commercial Cloud and Data Cloud.

• Veeva Commercial Summit Europe is scheduled for November 18-19, 2026, in Copenhagen.
• The summit will feature over 100 sessions and 1,200+ industry experts.
• AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB will present case studies.

IQVIA Expands Veeva Partnership with Clinical Operations Applications

IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.

• IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications.
• Partnership expansion extends the previously announced EDC partnership.
• All Veeva clinical solutions will be available through IQVIA for sponsors.